Pinpointing when T cell costimulatory receptor CTLA-4 must be engaged to dampen diabetogenic T cells.

Engagement of the T cell costimulatory receptor CTLA-4 can potently down-regulate an immune response. For example, in a T cell receptor transgenic mouse model of autoimmune diabetes, CTLA-4 interactions keep pancreatic islet-reactive T cells in check, evidenced by the finding that mAb blockade of CTLA-4 rapidly provokes diabetes in animals that would not normally succumb until many months later. Interestingly, this effect is only observed early in the course of disease, before insulitis is stably entrenched. Here, we have exploited a highly synchronous and easily manipulable transfer system to determine precisely when CTLA-4 must be engaged to check the diabetogenicity of islet-reactive T cells. Our results indicate that CTLA-4 interactions during initial priming of the T cells in the pancreatic lymph nodes are not determinant. Rather, the critical interactions occur when the T cells secondarily reencounter their antigen in the target organ, the pancreatic islets. In addition, we made use of CTLA-4-deficient mice to bolster our interpretation that CTLA-4 engagement has a dampening rather than an enhancing influence on diabetes progression.

[1]  J. Bluestone,et al.  B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes. , 2000, Immunity.

[2]  A. Khoruts,et al.  CTLA-4 blockade reverses CD8+ T cell tolerance to tumor by a CD4+ T cell- and IL-2-dependent mechanism. , 1999, Immunity.

[3]  A. Sharpe,et al.  The role of CTLA-4 in regulating Th2 differentiation. , 1999, Journal of immunology.

[4]  J. Allison,et al.  Cytotoxic T lymphocyte antigen-4 (CTLA-4) regulates primary and secondary peptide-specific CD4(+) T cell responses. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[5]  A. Sharpe,et al.  CTLA-4 and T cell activation. , 1999, Current opinion in immunology.

[6]  A. Sharpe,et al.  Opposing roles of CD28:B7 and CTLA-4:B7 pathways in regulating in vivo alloresponses in murine recipients of MHC disparate T cells. , 1999, Journal of immunology.

[7]  J. Allison,et al.  CTLA-4-Mediated inhibition of early events of T cell proliferation. , 1999, Journal of immunology.

[8]  E. Michaëlsson,et al.  CTLA-4 Ligation Suppresses CD28-induced NF-κB and AP-1 Activity in Mouse T Cell Blasts* , 1999, The Journal of Biological Chemistry.

[9]  K. McCoy,et al.  Cytotoxic T Lymphocyte–associated Antigen 4 (CTLA-4) Can Regulate Dendritic Cell–induced Activation and Cytotoxicity of CD8+ T Cells Independently of CD4+T Cell Help , 1999, The Journal of experimental medicine.

[10]  J. Allison,et al.  Costimulatory regulation of T cell function. , 1999, Current opinion in cell biology.

[11]  A. Sharpe,et al.  The role of CD80, CD86, and CTLA4 in alloimmune responses and the induction of long-term allograft survival. , 1999, Journal of immunology.

[12]  Andreas Hutloff,et al.  ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28 , 1999, Nature.

[13]  C. Benoist,et al.  Initiation of Autoimmune Diabetes by Developmentally Regulated Presentation of Islet Cell Antigens in the Pancreatic Lymph Nodes , 1999, The Journal of experimental medicine.

[14]  S. Khoury,et al.  Acquired thymic tolerance: role of CTLA4 in the initiation and maintenance of tolerance in a clinically relevant autoimmune disease model. , 1999, Journal of immunology.

[15]  J. Bluestone,et al.  Molecular basis of T cell inactivation by CTLA-4. , 1998, Science.

[16]  D. Farber,et al.  Differential role of CTLA-4 in regulation of resting memory versus naive CD4 T cell activation. , 1998, Journal of immunology.

[17]  S. Wahl,et al.  Engagement of Cytotoxic T Lymphocyte–associated Antigen 4 (CTLA-4) Induces Transforming Growth Factor β (TGF-β) Production by Murine CD4+ T Cells , 1998, The Journal of experimental medicine.

[18]  R. Flavell,et al.  Local expression of TNFalpha in neonatal NOD mice promotes diabetes by enhancing presentation of islet antigens. , 1998, Immunity.

[19]  A. Sharpe,et al.  The role of B7 co‐stimulation in activation and differentiation ofCD4+and CD8+T cells , 1998, Immunological reviews.

[20]  C. Thompson,et al.  Expression and function of CTLA-4 in Th1 and Th2 cells. , 1998, Journal of immunology.

[21]  J. Allison,et al.  Secondary but not primary T cell responses are enhanced in CTLA‐4‐deficient CD8+ T cells , 1998, European journal of immunology.

[22]  J. Allison,et al.  CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[23]  H. Reiser,et al.  Fas-independent death of activated CD4(+) T lymphocytes induced by CTLA-4 crosslinking. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[24]  C. Thompson,et al.  Brief Definitive Report Cytotoxic T Lymphocyte Antigen 4 (CTLA4) Blockade Accelerates the Acute Rejection of Cardiac Allografts in CD28-deficient Mice: CTLA4 Can Function Independently of CD28 , 2022 .

[25]  F. Fallarino,et al.  B7-1 Engagement of Cytotoxic T Lymphocyte Antigen 4 Inhibits T Cell Activation in the Absence of CD28 , 1998, The Journal of experimental medicine.

[26]  Y. Wu,et al.  B7-CTLA4 interaction enhances both production of antitumor cytotoxic T lymphocytes and resistance to tumor challenge. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[27]  J. Bluestone,et al.  CTLA-4 regulates tolerance induction and T cell differentiation in vivo. , 1998, Journal of immunology.

[28]  C. Benoist,et al.  Cytotoxic T Lymphocyte–associated Antigen 4 (CTLA-4) Regulates the Unfolding of Autoimmune Diabetes , 1998, The Journal of experimental medicine.

[29]  T. Mak,et al.  Normal responsiveness of CTLA-4-deficient anti-viral cytotoxic T cells. , 1998, Journal of immunology.

[30]  M. Mattéi,et al.  Genetic control of diabetes progression. , 1997, Immunity.

[31]  J. Allison,et al.  Thymocyte development is normal in CTLA-4-deficient mice. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[32]  T. Mak,et al.  Normal thymic selection, normal viability and decreased lymphoproliferation in T cell receptor‐transgenic CTLA‐4‐deficient mice , 1997, European journal of immunology.

[33]  B. Foster,et al.  Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[34]  K. McCoy,et al.  Protective Immunity to Nematode Infection Is Induced by CTLA-4 Blockade , 1997, The Journal of experimental medicine.

[35]  Yan Wu,et al.  CTLA-4–B7 Interaction Is Sufficient to Costimulate T Cell Clonal Expansion , 1997, The Journal of experimental medicine.

[36]  T. Strom,et al.  Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement. , 1997, Immunity.

[37]  C. June,et al.  CTLA-4 blockade enhances clinical disease and cytokine production during experimental allergic encephalomyelitis. , 1996, Journal of immunology.

[38]  Nitin J. Karandikar,et al.  CTLA-4: a negative regulator of autoimmune disease , 1996, The Journal of experimental medicine.

[39]  J. Bluestone,et al.  CTLA-4 ligation blocks CD28-dependent T cell activation [published erratum appears in J Exp Med 1996 Jul 1;184(1):301] , 1996, The Journal of experimental medicine.

[40]  J. Allison,et al.  CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells , 1996, The Journal of experimental medicine.

[41]  T. Sullivan,et al.  Superantigen responses and co-stimulation: CD28 and CTLA-4 have opposing effects on T cell expansion in vitro and in vivo. , 1996, International immunology.

[42]  J. Allison,et al.  Enhancement of Antitumor Immunity by CTLA-4 Blockade , 1996, Science.

[43]  H. Griesser,et al.  Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4 , 1995, Science.

[44]  J. Bluestone,et al.  Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. , 1995, Immunity.

[45]  R. Karr,et al.  Antigen-dependent clonal expansion of a trace population of antigen-specific CD4+ T cells in vivo is dependent on CD28 costimulation and inhibited by CTLA-4. , 1995, Journal of immunology.

[46]  P. Linsley,et al.  Distinct roles for CD28 and cytotoxic T lymphocyte-associated molecule- 4 receptors during T cell activation? , 1995, The Journal of experimental medicine.

[47]  J. Allison,et al.  CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation , 1995, The Journal of experimental medicine.

[48]  C Benoist,et al.  T helper cell subsets in insulin-dependent diabetes. , 1995, Science.

[49]  P. Linsley,et al.  CTLA-4 can function as a negative regulator of T cell activation. , 1994, Immunity.

[50]  A. B. Lyons,et al.  Determination of lymphocyte division by flow cytometry. , 1994, Journal of immunological methods.

[51]  C. Benoist,et al.  Following a diabetogenic T cell from genesis through pathogenesis , 1993, Cell.

[52]  P. Linsley,et al.  Coexpression and functional cooperation of CTLA-4 and CD28 on activated T lymphocytes , 1992, The Journal of experimental medicine.

[53]  S. Rastan,et al.  Lymphoid development in mice congenitally lacking T cell receptor alpha beta-expressing cells. , 1992, Science.

[54]  K. Haskins,et al.  Acceleration of diabetes in young NOD mice with a CD4+ islet-specific T cell clone. , 1990, Science.

[55]  C. Benoist,et al.  MHC-linked protection from diabetes dissociated from clonal deletion of T cells. , 1990, Science.